Pharma
sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Most Viewed Abstracts



Your Article Summary

See Latest Articles
(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Positive Phase II Results for GSK1838262 Reported for Subjects with Post-Herpetic Neuralgia and a History of Inadequate Response to Gabapentin
XenoPort, 10/06/09

GlaxoSmithKline and XenoPort, Inc. announced top–line results from a Phase II clinical trial evaluating GSK1838262/XP13512 in adult patients with neuropathic pain associated with post–herpetic neuralgia who have had a history of inadequate response to gabapentin doses of 1800 mg/day or higher.

Today in Drug Trials...keeping you current

Association of trial registration with the results and conclusions of published trials of new oncology drugs
Trials, 12/17/09

Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09

Sanofi Pasteur expands study of vaccine against Clostridium difficile into the U.S.
Sanofi-aventis, 12/16/09

 See all of Drug Trials

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address